Pfizer Inc, a US pharmaceutical company on Monday injected one patient in the US with its experimental COVID-19 vaccine.
The company has partnered with Germany’s BioNTech SE, and the trials for the vaccine are being conducted at the New York University Grossman School of Medicine in Manhattan and the University of Maryland School of Medicine in Baltimore, the company said in a statement on Tuesday.
According to researchers, the vaccine uses an RNA-based technology, which requires four doses of treatment. The RNA slips faster into human cells and triggers the production of the viral proteins that then leads to the formation of protective antibodies.
“The short, less than four-month time-frame in which we’ve been able to move from pre-clinical studies to human testing is extraordinary,” Pfizer’s chief executive officer Albert Bourla was quoted as saying by the media.
A total of 360 corona patients between the age groups of 18 and 55 will undergo vaccine trials and the results will come next month.
Based on the trails, the suitable vaccine candidates if successful in neutralizing coronavirus will be taken for approval, the researchers added.
